Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Confo Therapeutics N.V.
Headquarters: Ghent, Belgium
Website: https://www.confotherapeuti...
Year Founded: 2015
Status: Private
BioCentury | Feb 12, 2025
Discovery & Translation
Pain targets in ion channel pathways: an Innovation Distillery spotlight
Upstream regulators of ion channel expression or function are an emerging frontier for novel pain targets
BioCentury | Sep 13, 2024
Data Byte
PanTera largest Belgian A round to date
Only nine other biotechs have raised over $25 million since 2015
BioCentury | Aug 7, 2024
Emerging Company Profile
Diagonal: Gluing receptor complexes back together
Newco uses AI/ML to find bispecific antibodies that can reassemble functional receptor complexes in the face of mutations
BioCentury | Aug 1, 2024
Finance
Venture Report: venBio closes new $528M fifth fund
Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers
BioCentury | Sep 13, 2023
Management Tracks
CEO Nick Leschly shifting to chair as 2seventy bio restructures
Plus: CFO Galá promoted at Jazz, and updates from Geron, Mirum, ReNAgade,
BioCentury | Aug 29, 2023
Management Tracks
Crossover-backed Arbor names Tamboli CFO
Plus: Atkinson named chief technical operations officer at Vertex, and updates from Confo, Flagship, Citryll and more
BioCentury | Aug 1, 2023
Deals
Pharma deals seek novelty with heavy focus on first in class
An analysis of the products, technologies and targets that have attracted global pharma deals over past 12 months
BioCentury | Mar 31, 2023
Product Development
March 31 Quick Takes: Cytokinetics to discontinue reldesemtiv ALS Phase III
Plus: Zealand raises $216.4M and updates from Confo, Daiichi and SineuGene
BioCentury | Mar 2, 2023
Deals
Lilly adds to clinical pain pipeline via deal with Belgium’s Confo
Private European company gets $40M up front for AGTR2-targeting small molecule in Phase I; deal also includes preclinical antibody
BioCentury | Feb 11, 2021
Finance
Belgium’s V-Bio looking for bigger bets in and out of its home country with
Firm seeks to groom management teams returning to start-ups
Items per page:
1 - 10 of 25